Immunological defects in severe mucocutaneous HSV-2 infections: response to IFNγ therapy

Publication date: Available online 7 April 2016
Source:Journal of Allergy and Clinical Immunology
Author(s): Peer Arts, Frank L. van de Veerdonk, Robin van der Lee, Martijn A. Langereis, Christian Gilissen, Wendy A.G. van Zelst-Stams, Martijn A. Huynen, Jos W.M. van der Meer, Frank J. van Kuppeveld, Joris A. Veltman, Bart Jan Kullberg, Alexander Hoischen, Mihai G. Netea

Teaser

Immune defects in dsRNA recognition and IFNγ production underlie susceptibility to severe reactivations with HSV-2. Treatment with recombinant IFNγ shows clinical efficacy, and it should be considered in patients with severe recurrent HSV-2 infections.


from #Esophageal Cancer via a.lsfakia on Inoreader http://ift.tt/1MUtQSe
via IFTTT